您当前所在的位置:首页 > 产品中心 > 产品信息
Betamethasone_分子结构_CAS_378-44-9)
点击图片或这里关闭

Betamethasone

产品号 DB00443 公司名称 DrugBank
CAS号 378-44-9 公司网站 http://www.ualberta.ca/
分子式 C22H29FO5 电 话 (780) 492-3111
分子量 392.4610632 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 326

产品价格信息

请登录

产品别名

标题
Betamethasone
IUPAC标准名
(1R,2S,10S,11S,13S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
IUPAC传统名
betamethasone
商标名
Betnelan
Betapredol
Betasolon
Betamethazone
Bedifos
Alphatrex
Becort
Betacorlan
Betafluorene
Betametasona [INN-Spanish]
Betamethasone Alcohol
Betamethasone Cream
Betamethasonum [INN-Latin]
Flubenisolone
Luxiq
Maxivate
Beta-Methasone
Beta-Methasone Alcohol
Betacortril
Betaderm
Betadexamethasone
Betamethasone Dipropionate
Betamethasone Valearate
Betamethasonvalerat Mikron
Betatrex
Betsolan
Celestene
Celestone
Celestone Syrup and Tablets
Cidoten
Diproderm
Diprolene
Diprolene AF
Diprosone
Luxiqo
Methazon
Rinderon
Rinderon A
Valnac
Bebate
Beta-Val
Betamamallet
Betametasone [DCIT]
Betamethasone Base
Betamethasone Sodium Phosphate
Betamethasone Valerate
Betamethasone [Usan:Ban:Inn:Jan]
Dermabet
Desacort-Beta
Hormezon
Lotrisone
Uticort
Valisone
Visubeta

产品登记号

PubChem SID 46505155
CAS号 378-44-9
PubChem CID 9782

产品性质

疏水性(logP) 1.1
溶解度 Insoluble

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
Indication Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp
Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.
Pharmacology Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.
Toxicity Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic
Absorption Minimal if applied topically.
Half Life 5.6 hours
Protein Binding 64%
External Links
Wikipedia
RxList
Drugs.com

参考文献